Colorectal cancer, called colorectal cancer, can be fatal and affect thousands of individuals around the world. The National Cancer Institute estimates that by 2022, there will be 151,030 new colorectal cancer cases and 52,580 colorectal cancer deaths in the United States.
Regarding the treatment of colorectal cancer, the American Cancer Society states that the method of treatment depends on the stage of the cancer. Surgical excision is the primary method of treatment, unless colorectal cancer has spread to other sites, with the possibility of other treatments such as chemotherapy and radiation. Immunotherapy alters cancer treatment and immune control inhibitors, an important feature of immunotherapy must be taken into account. In a recent study published in The New England Journal of Medicine, the researchers found that the use of inhibitors of participatory immune control can be very beneficial in treating patients with rectal cancer and completely eradicating malignant cells. Treatment may be effective enough to eliminate the need for surgery. The study consisted of 12 adult participants with locally advanced rectal cancer mismatch (MMR) deficiency in stage I or stage II. Researchers believe that this type of cancer can be effectively treated with immunotherapy, which helps the human body more effectively detect and fight cancer cells.
The research team used an immune control inhibitor known as dostarlimab, an inhibitor of programmed cellular protein 1 (PD-1). Anti-PD-1 therapy is aimed at preventing immune depletion of cancer cells. Participants received dostarlimab intravenously (i.v.) every three weeks for approximately six months.
Students responded well to dosarlimab treatment. Importantly, none of the participants had evidence of a tumor at the end of the clinical study, and none of them had to undergo additional chemotherapy or surgery at the end of the study. To date, all study participants have completed a six-month follow-up. Prof. John Bridgewater, a clinical researcher at University College London Cancer Institute who specializes in gastrointestinal medical oncology and was not included in the study, said: “These data show a more effective use of immunotherapy, especially the checkpoint inhibitor. rectal cancer with insufficient repair […]. ”
The authors of this study state that “These findings need to be replicated in a larger prospective cohort that balances academic and community practices and ensures patient participation from diverse and diverse backgrounds. Ethnic backgrounds.”
Dr. Hopefully, the study contributes to the growing evidence that understanding the type of cancer can affect treatment. He said: “Patients need to be able to understand the biology of their cancer. We are working to inform patients that they have a certain subtype of rectal cancer. It really shows the power of biomarkers and appropriate drugs.” If you treat all patients with rectal cancer with a checkpoint blocker, you will not see this response rate. Wherever patients are, it is important that they talk to their doctors and find out as much as they can about their cancer. Their therapies can vary widely based on these results. ”
The results of the study showed that immune checkpoint inhibitors could effectively eliminate tumor cells in patients with colorectal cancer, and the result was better in patients with a genetic MMR abnormality; however, larger sample sizes and longer follow-up evaluations are needed to validate the study results. Further research should be conducted to determine the cause of poor immune control in metastatic colorectal cancers.